MetaCap

CalciMedica (CALC) vs Radiopharm Theranostics (RADX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Radiopharm Theranostics (RADX) has outperformed CalciMedica (CALC) over the past year, losing 86.1% versus a loss of 92.3%. Radiopharm Theranostics is the larger company by market cap ($9.9 million vs $8.7 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CALC-92.34%RADX-86.15%
+145%+20%-105%
Nov 21, 20251 yearNov 20, 2026
CALC-91.19%RADX-96.66%
+147%+19%-108%
Dec 2, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CALC versus RADX key metrics
MetricCALCRADX
Share price$1.26$0.6304
Market cap$8.69M$9.90M
1-day change+7.69%-9.71%
YTD return-96.18%-87.92%
1-year return-92.34%-86.15%
EPS (TTM)$-4.41$-3.64
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$3.63M
Revenue growth (YoY)—+1114.27%
Net income (latest FY)$-29.56M$-38.34M
Gross margin—1.08%
Operating margin—-1050.63%
Net margin—-1055.27%
52-week high$36.00$16.25
52-week low$1.00$0.63
Distance from 52-week high-96.50%-96.12%
Analyst consensusnonestrong_buy
Avg. price target upside+3868.25%+2595.11%
Average volume80.15K55.23K
Shares outstanding6.90M15.70M
Employees1514
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About CalciMedica

CALC stock →

CalciMedica, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. Its lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated calcium (CRAC) channel inhibitors for the treatment of acute pancreatitis, asparaginase-induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.

Health Care · Biotechnology: Pharmaceutical Preparations · 15 employees

About Radiopharm Theranostics

RADX stock →

Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic.

Health Care · Biotechnology: Pharmaceutical Preparations · 14 employees

CALC vs RADX FAQ

Which is bigger, CalciMedica or Radiopharm Theranostics?

Radiopharm Theranostics (RADX) is larger, with a market capitalization of $9.90M compared with $8.69M for CalciMedica (CALC).

Which stock has performed better over the past year, CALC or RADX?

RADX returned -86.15% over the past 12 months, compared with -92.34% for CALC (price return, excluding dividends). Past performance does not predict future results.

Are CalciMedica and Radiopharm Theranostics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons